# A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Source: https://onco.cc/trials/nct05181540/  
OnCo record `nct05181540` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of AB-205 run by Angiocrine Bioscience, terminated.

## Summary

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation is a phase 3 interventional study registered as NCT05181540 by Angiocrine Bioscience, with 130 participants enrolled, started 2022-02-21. Conditions recorded: Hodgkin Lymphoma and Non Hodgkin Lymphoma. Interventions recorded: AB-205 and Placebo.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05181540
- Phase: 3
- Setting: A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
- Sponsor: Angiocrine Bioscience
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT05181540: https://clinicaltrials.gov/study/NCT05181540

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AB-205](https://onco.cc/drugs/ab-205/)
- companies: [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct05181540.json